Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Brigatinib for Brain Tumor
Recruiting1 awardPhase 2
Rochester, Minnesota
This trial is testing brigatinib, a drug for patients with brain metastases from anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). This study is for patients who have not been treated with a similar drug before or who have had prior exposure to crizotinib.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.